GeoVax Labs, Inc. (GOVX)

1,4438 -0,0262 (-1,78%) A partir del 01:47PM EDT. Mercado abierto.

GeoVax Labs, Inc.

1900 Lake Park Drive
Suite 380
Smyrna, GA 30080
United States
678 384 7220
https://www.geovax.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 17

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. David Alan Dodd	Chairman, President & CEO	384,2k	N/A	1950
Dr. Mark J. Newman Ph.D.	Chief Scientific Officer	291,5k	N/A	1955
Dr. Kelly T. McKee Jr., M.D., M.P.H.	Chief Medical Officer	361,03k	N/A	1951
Dr. Harriet Latham Robinson Ph.D.	Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board	N/A	N/A	1938
Mr. Thomas O'Brien	Vice President of Quality Systems & Compliance	N/A	N/A	N/A
Mr. Jeffrey Welch	Head of Process Development & Manufacturing Operations	N/A	N/A	N/A
Mr. John Niles	Head of Commercial Operations	N/A	N/A	N/A
Dr. John W. Sharkey Ph.D.	Vice President of Business Development	N/A	N/A	1956

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Gobierno corporativo

El ISS Governance QualityScore de GeoVax Labs, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.